Life Sciences Laboratory Products > Purecell™ Select System for Whole Blood MNC Enrichment

Purecell™ Select System for Whole Blood MNC Enrichment

Print Product Information

E-Mail

Rapid, easy-to-use, filter-based technology for the enrichment of mononuclear cells

Pall’s novel Purecell Select System revolutionizes the enrichment of mononuclear cells (MNC) with a new filtration-based platform that is fast, easy to use, and produces consistently high cell recoveries. The system frees scientists from traditional lab-based methodologies such as density gradient centrifugation that are known to be time consuming and labor intensive.

Accelerated processing – Achieve enrichment of MNC from 20 to 120 mL of whole blood in 15 minutes or less.
Easy to use – Simply transfer the sample to the sample input bag, filter the sample, then back-flush the Harvest Solution through the filter, collecting the enriched MNC in a collection bag. During the filtration process, the majority of the plasma, red blood cells, and platelets pass through the filter into the waste bag below. The MNC are captured on the filter and released during the back-flush process with the optimized Harvest Solution. No capital equipment or special training is required.
Consistent results – With the Purecell Select System, the uniquely designed filter and optimized Harvest Solution do all the difficult cell separation work. This results in a highly robust process with consistent results, critical when working with highly variable biologic samples. Using a filtration-based platform minimizes operator training and variability between operators, resulting in a more predictable cell yield.
Higher cell recovery – MNC recovery from 50 mL whole blood consistently averages > 70%. The Purecell Select System consistently recovers 20 to 50% more MNC than Ficoll* processing.
Increased level of safety – The risk of sample contamination and biohazard exposure is reduced in this smart-set design by incorporating needleless access ports and eliminating open-tube processing.

For research use only. Not for human use.

*Ficoll is a trademark of GE Healthcare companies.

ORDER NOW

Smart-set Design

The consistent performance and usability of the Purecell Select System has been thoughtfully engineered. The Purecell Select System combines a number of unique design features including:

Filter materials that capture and release the cells of interest
Filter housing that ensures a reliable media seal and optimal flow characteristics
Single-use set that incorporates Pall’s easy-to-use bag technology
Valve ports that engage with luer fittings to eliminate the need for needles
Optimized Harvest Solution to maximize cell recovery

The Purecell Select System's smart-set design includes everything needed for the enrichment of MNC from a whole blood or cord blood sample; no additional equipment is required. Designed for single use, the system is disposable and features a sterile, non-pyrogenic fluid path. All materials meet safety and biocompatibility requirements. The system components and process for the Purecell Select System are configured to assure minimal user intervention. Only three steps require user activity:

Add sample
Filter
Recover MNC

Purecell Select System's smart-set design

Purecell Select System Advantage

For many applications, the easy-to-use Purecell Select System can replace centrifugation-based gradient methods and thus, the technician manipulations those methods demand. This translates to:

Consistently higher recoveries of MNC.
Improved ease of use, reducing processing steps and processing variables.
Fast processing in 15 minutes or less.
A sterile fluid path for filtration and separation with no open-tube processing step, minimizing the opportunity for contamination.

The Purecell Select System is manufactured to cGMP standards using validated manufacturing processes that ensure safe, consistent and reliable product performance. Pall customers can be sure that “Reliability by Design” is built into every Purecell Select System.

The all-in-one Purecell Select System includes the filter harvest set, cell collection bag, 30 mL sterile syringes, Harvest Solution, and sterile vial adaptor.

ORDER NOW

Technical Application Notes - Read the Detailed Data

A Quick Look at This Fast, High-Yield Alternative to Traditional Density Gradient Centrifugation

Pall’s Purecell Select System is an alternative technology to density gradient centrifugation for the enrichment of MNC from whole blood or cord blood. Many density separation media are available commercially, of which Ficoll-Paque* is the most widely used.

Pall’s filtration-based system provides researchers with an alternative enrichment technology that is significantly faster than traditional methods and results in a higher cell yield than Ficoll separations. The MNC recovery from the Purecell Select System typically averages > 70% (Figure 1). MNC recovery across the WB volume range processed by the Pall system (20 to 120 mL) typically averages > 65% (data not shown).

Percent Recovery of Major Leukocyte Populations

Percent recovery of major cell types in 50 mL WB starting material, Purecell Select System processed samples and Ficoll samples. Percent recovery is calculated based on WBC, platelet and red blood cell (RBC) concentration (Cell-Dyn* 1800); percent lymphocytes, monocytes and granulocytes is based on phenotype data (BD FACSCalibur system). Duplicates are averaged. Means +/- 1 SD from 6 donors are reported.

Phenotypic analysis of processed samples shows that the Purecell Select System yields more cells of all major types than are recovered with Ficoll separations (Figure 2). The cell population from the Purecell Select System differs from the cell population recovered from Ficoll in that the cell population from the Pall system has a higher concentration of granulocytes and red blood cells. Researchers will need to assess the specific requirements of their applications. Protocol modifications can reduce the residual red blood cell concentration.

Total Cell Number of Major Leukocyte Populations

Total number of major cell types in 50 mL WB and processed samples. Phenotype data (BD FACSCaliber system) averages from 6 donors +/- 1 SD are reported.

Cell viability at 24 hours using propidium iodide is comparable to cell viability from Ficoll processing.

Viability of WBC Population


WB	Purecell Select System	Ficoll
95.7% +/- 1.5	96.0% +/- 1.4	97.3% +/- 3.2

Percent viability of white blood cells (WBC) was determined by dye exclusion using propidium iodide. The percent viability was calculated by the percentage of unstained versus total cells as determined by flow cytometry (BD FACSCalibur* system). N=5.

*Ficoll and Ficoll-Paque are trademarks of GE Healthcare companies. Cell-Dyn is a registered trademark of Abbott Laboratories. BD FACSCalibur is a trademark of BD Biosciences.


Part Number	Description	Pkg	Price	Qty
Purecell™ Select System for Whole Blood MNC Enrichment (See Contact Us to order outside USA)
999-02	Each Purecell Select System includes: 1 filter harvest set; 1 cell collection bag; 2, 30 mL sterile syringes; 1 Harvest Solution in a septum-sealed bottle; 1 sterile vial adapter for retrieving Harvest Solution; 1 instructions for use	1/pkg	99.00

Your shopping cart is empty.

*US List Price applies only to products delivered within the US. These prices do not reflect duties, taxes or tariffs, which may apply to purchases made outside of the US. See our General Limited Warranty.

Purecell™ Select System for Whole Blood MNC Enrichment

Rapid, easy-to-use, filter-based technology for the enrichment of mononuclear cells

*Ficoll is a trademark of GE Healthcare companies.

Smart-set Design

Purecell Select System Advantage

Sample Type

Anticoagulants

Sample Volume

Operating Temperature

Materials of Construction

Biological Safety

Sterilization

Dimensions

Storage Conditions

Shelf Life

Traceability

Regulatory

Manufacturing

Technical Application Notes - Read the Detailed Data

A Quick Look at This Fast, High-Yield Alternative to Traditional Density Gradient Centrifugation

Percent Recovery of Major Leukocyte Populations

Total Cell Number of Major Leukocyte Populations

Total number of major cell types in 50 mL WB and processed samples. Phenotype data (BD FACSCaliber system) averages from 6 donors +/- 1 SD are reported.

Viability of WBC Population

Percent viability of white blood cells (WBC) was determined by dye exclusion using propidium iodide. The percent viability was calculated by the percentage of unstained versus total cells as determined by flow cytometry (BD FACSCalibur* system). N=5.

*Ficoll and Ficoll-Paque are trademarks of GE Healthcare companies. Cell-Dyn is a registered trademark of Abbott Laboratories. BD FACSCalibur is a trademark of BD Biosciences.